<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02531360</url>
  </required_header>
  <id_info>
    <org_study_id>MNI-815</org_study_id>
    <nct_id>NCT02531360</nct_id>
  </id_info>
  <brief_title>Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Tauopathies</brief_title>
  <official_title>Phase 0 Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Alzheimer's Disease and Other Tauopathies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Molecular NeuroImaging</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Piramal Imaging SA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Molecular NeuroImaging</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall goal of this imaging trial is to characterize [18F]MNI-815, a PET radioligand for
      imaging Tau.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Brain uptake of [18F]MNI-815</measure>
    <time_frame>18 months</time_frame>
    <description>The PET imaging outcome measure to evaluate tau burden will be the standardized uptake value (SUV), which will be calculated for the areas of interest by using the established methods for normalizing to subject weight and injected dose.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Alzheimer's Disease (AD)</condition>
  <condition>Progressive Supranuclear Palsy (PSP)</condition>
  <condition>Cortical Basal Syndrome (CBS)</condition>
  <condition>Frontal Temporal Dementia (FTD)</condition>
  <arm_group>
    <arm_group_label>[18F]MNI-815 (MNI-815)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>At the [18F]MNI-815 PET imaging visit, subjects will be injected with no more than 10mCi of [18F]MNI-815</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[18F]MNI-815 (MNI-815)</intervention_name>
    <description>All enrolled subjects will undergo an [18F]MNI-815 PET imaging visit. As a part of the screening visit, subjects will undergo [18F]florbetaben (FBB) PET imaging to determine if they have significant amyloid deposition.</description>
    <arm_group_label>[18F]MNI-815 (MNI-815)</arm_group_label>
    <other_name>[18F]MNI-815</other_name>
    <other_name>FBB</other_name>
    <other_name>[18F]Florbetaben</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        For all subjects:

          -  Written informed consent must be obtained before any assessment is performed.

          -  Female subjects must be either surgically sterile (by means of hysterectomy, bilateral
             oophorectomy, or tubal ligation) or post-menopausal for at least 1 year or, if they
             are child-bearing potential, must commit to use of a barrier contraception method for
             the duration of the study.

          -  Male subjects and their partners of childbearing potential must commit to the use of
             two methods of contraception, one of which is a barrier method for male subjects for
             the study duration

          -  Willing and able to cooperate with study procedures

        Healthy Control subjects:

          -  Males and females aged between 50 - 70 years. Healthy with no clinically relevant
             finding on physical examination at screening and upon reporting for the [18F]MNI-815
             imaging visit.

          -  No cognitive impairment from neuropsychological battery as judged by the investigator

          -  Have a CDR score=0

          -  Has FBB PET imaging demonstrating no evidence for significant amyloid binding based on
             qualitative (visual read) and quantitative analysis.

          -  Modified Hachinski Ischemia Scale score of ≤ 4.

        Prodromal or Moderate Alzheimer's Disease subjects:

          -  Males and females aged between 50 - 90 years.

          -  Have prodromal or moderate Alzheimer's disease, based on the NINCDS/ADRDA and DSM-IV
             criteria.

          -  Have a CDR score of 0.5 for prodromal AD subjects and CDR &gt; 1.0 for moderate AD
             subject at screening.

          -  Has a FBB PET imaging demonstrating amyloid binding based on qualitative (visual read)
             and quantitative analysis.

          -  Modified Hachinski Ischemia Scale score of ≤ 4.

          -  A brain MRI that supports a diagnosis of AD, with no evidence of focal disease to
             account for dementia or MRI exclusion criteria.

          -  Medications taken for symptomatic treatment of AD must be maintained on a stable
             dosage regimen for at least 1 month before the [18F]MNI-815 imaging visit.

          -  The subject has an appropriate caregiver capable of accompanying subject on all
             visits.

          -  Signed and dated written informed consent obtained from the subject and, when
             applicable, the subject's legally authorized representative or caregiver.

        Frontotemporal Dementia subjects:

          -  Has a clinical diagnosis of FTD based on consensus for clinical diagnosis of
             frontotemporal dementia criteria (Neary, et al 1998)

          -  Has a FBB PET imaging demonstrating no evidence of significant amyloid binding based
             on qualitative (visual read) and quantitative analysis.

          -  A brain MRI that supports a diagnosis of FTD, with no evidence of focal disease to
             account for dementia or MRI exclusion criteria.

          -  Medications taken for symptomatic treatment of cognitive dysfunction must be
             maintained on a stable dosage regimen for at least 1 month before the screening visit.

          -  The subject has an appropriate caregiver capable of accompanying subject on all visits
             to the center.

          -  Signed and dated written informed consent obtained from the subject and, when
             applicable, the subject's legally authorized representative or caregiver.

          -  Modified Hachinski Ischemia Scale score of ≤ 4.

        Progressive Supranuclear Palsy subjects:

          -  Has a clinical diagnosis of PSP based the NINDS and Society for PSP criteria (Litvan,
             et al 1996)

          -  Has FBB PET imaging demonstrating no evidence of significant amyloid binding based on
             qualitative (visual read) and quantitative analysis.

          -  A brain MRI that supports a diagnosis of PSP, with no evidence of focal disease to
             account for dementia or MRI exclusion criteria.

          -  Medications taken for treatment of PSP symptoms must be maintained on a stable dosage
             regimen for at least 1 month before the screening visit.

          -  The subject has an appropriate caregiver capable of accompanying subject on all visits
             to the center.

          -  Signed and dated written informed consent obtained from the subject and, when
             applicable the subject's legally authorized representative or caregiver.

          -  Modified Hachinski Ischemia Scale score of ≤ 4.

        Corticobasal Syndrome Subjects:

          -  Has a clinical diagnosis of CBS based on consensus criteria for possible or probable
             corticobasal degeneration (Armstrong et al, 2013)

          -  Has a FBB PET imaging demonstrating no evidence of significant amyloid binding based
             on qualitative (visual read) and quantitative analysis.

          -  A brain MRI that supports a diagnosis of CBS, with no evidence of focal disease to
             account for dementia or MRI exclusion criteria.

          -  Medications taken for treatment of CBS symptoms must be maintained on a stable dosage
             regimen for at least 1 month before the screening visit.

          -  The subject has an appropriate caregiver capable of accompanying subject on all visits
             to the center.

          -  Signed and dated written informed consent obtained from the subject and, when
             applicable, the subject's legally authorized representative or caregiver.

          -  Modified Hachinski Ischemia Scale score of ≤ 4.

        Exclusion Criteria:

        For all subjects

          -  Current or prior history of any alcohol or drug abuse.

          -  Laboratory tests with clinically significant abnormalities and/or clinically
             significant unstable medical illness.

          -  Prior participation in other research protocols or clinical care in the last year such
             that radiation exposure is &gt;15 mSv and would exceed the annual limits.

          -  Pregnancy or breastfeeding.

          -  Evidence of clinically significant gastrointestinal, cardiovascular, hepatic, renal,
             hematological, neoplastic, endocrine, alternative neurological, immunodeficiency,
             pulmonary, or other disorder or disease.

          -  Unsuitable veins for repeated venipuncture.

          -  MRI exclusion criteria include: Pathology that may be responsible for the neurologic
             status of the patient such as infectious disease, space-occupying lesions, normal
             pressure hydrocephalus or any other abnormalities associated with CNS disease,

          -  Implants such as implanted cardiac pacemakers or defibrillators, insulin pumps,
             cochlear implants, metallic ocular foreign body, implanted neural stimulators, CNS
             aneurysm clips and other medical implants that have not been certified for MRI, or
             history of claustrophobia in MRI.

        Exclusion criteria for subjects with AD subjects:

          -  Has received treatment that targeted amyloid-beta or tau within the last 24 months.

          -  Has a FBB PET imaging demonstrating no evidence of significant amyloid binding
             irrespective of other previous measurements of beta amyloid that may be available for
             review.

        Exclusion criteria for subjects with PSP or CBS subjects:

          -  Has FBB PET imaging with evidence of significant amyloid binding irrespective of other
             previous measurements of beta amyloid that may be available for review.

          -  Has received treatment that targeted tau within the last 24 months.

          -  Have any other neurological condition other than CBS or PSP that could account for
             cognitive or motor deficits including: Specifically:

          -  A diagnosis of idiopathic Parkinson's disease or Lewy body dementia and/or have a
             prominent and sustained response to levodopa therapy;

          -  History of repeated strokes with stepwise progression of parkinsonian features or
             history of major stroke

        FTD subjects:

          -  Has FBB PET imaging with evidence of significant amyloid binding irrespective of other
             previous measurements of beta amyloid that may be available for review.

          -  Has received treatment that targeted tau within the last 24 months.

        Healthy subjects:

        •Has FBB PET imaging with evidence of significant amyloid binding irrespective of other
        previous measurements of beta amyloid that may be available for review.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Danna Jennings, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Molecular NeuroImaging, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Molecular NeuroImaging, LLC</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mnimaging.com</url>
    <description>Molecular NeuroImaging</description>
  </link>
  <link>
    <url>http://indd.org</url>
    <description>Institute for Neurodegenerative Disorders</description>
  </link>
  <reference>
    <citation>Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, Freedman M, Kertesz A, Robert PH, Albert M, Boone K, Miller BL, Cummings J, Benson DF. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology. 1998 Dec;51(6):1546-54. Review.</citation>
    <PMID>9855500</PMID>
  </reference>
  <reference>
    <citation>Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin RC, Goetz CG, Golbe LI, Grafman J, Growdon JH, Hallett M, Jankovic J, Quinn NP, Tolosa E, Zee DS. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology. 1996 Jul;47(1):1-9. Review.</citation>
    <PMID>8710059</PMID>
  </reference>
  <reference>
    <citation>Armstrong MJ, Litvan I, Lang AE, Bak TH, Bhatia KP, Borroni B, Boxer AL, Dickson DW, Grossman M, Hallett M, Josephs KA, Kertesz A, Lee SE, Miller BL, Reich SG, Riley DE, Tolosa E, Tröster AI, Vidailhet M, Weiner WJ. Criteria for the diagnosis of corticobasal degeneration. Neurology. 2013 Jan 29;80(5):496-503. doi: 10.1212/WNL.0b013e31827f0fd1.</citation>
    <PMID>23359374</PMID>
  </reference>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 9, 2015</study_first_submitted>
  <study_first_submitted_qc>August 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 24, 2015</study_first_posted>
  <last_update_submitted>December 15, 2016</last_update_submitted>
  <last_update_submitted_qc>December 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Molecular NeuroImaging</investigator_affiliation>
    <investigator_full_name>Danna Jennings</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Supranuclear Palsy, Progressive</mesh_term>
    <mesh_term>Tauopathies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

